Breast Cancer Therapeutics Market - By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), Global Forecast, 2023-2032

Breast Cancer Therapeutics Market Size

Breast Cancer Therapeutics Market size was around USD 26.7 billion in 2022 and is expected to reach USD 54.7 billion by 2032. The growing incidence of breast cancer is amongst the major factors stimulating the market growth.
 

According to the International Agency for Research on Cancer (WHO), in 2021, the incidence of breast cancer was more than 2.2 million, accounting for approximately 11.7% of the total cancer cases globally. Further, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence and mortality rate associated with breast cancer is expected to render significant impact, driving the market progress.
 

Breast cancer therapeutics can be defined as the treatment or management of breast cancer using therapeutic approach & drugs such as chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. These oncology drugs/therapeutics abduct the growth and multiplication of cancerous cells by disrupting certain proteins or DNA.
 

COVID-19 Impact

The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed. According to the National Centers for Biotechnology Information (NCBI) article, in 2021, the COVID-19 pandemic caused delays in the screening and treatment of breast cancer patients owing to fear of infection and lockdown. The study reported a 15% drop in breast cancer patients admitted during the coronavirus outbreak. As a result, the market witnessed slow growth owing to delayed breast cancer diagnosis and treatment, although the industry is expected to follow the growth trajectory in the coming years.
 

Breast Cancer Therapeutics Market Trends

Initiation of breast cancer awareness and screening programs by the regional government authorities to curb the mortality rates associated with breast cancer is anticipated to prove conducive for the market expansion.
 

• Breast cancer therapeutics are increasingly effective while treating breast cancer and delivers more than 90% survival probabilities, especially when the disease is diagnosed at an early stage. As per the NCBI article, in 2017, breast cancer screening programs aid in early detection, prevention of risk factors, optimal treatment to lower the morbidity, and promote survival rate.
   
• Moreover, adoption of breast cancer awareness campaigns by public organizations is projected to promote the education regarding breast cancer and breast cancer therapeutics. For instance, the National Breast Cancer Foundation initiated “October as a Breast Cancer Awareness Month”, a campaign to drive awareness concerning the impact of breast cancer. Such initiatives are expected to encourage the diagnosed breast cancer patients to opt for optimal breast cancer therapeutics, further driving the survival rate of breast cancer therapeutics that is expected to drive the market demand.
   

Breast Cancer Therapeutics Market Analysis

Based on therapy type, the market is segmented into targeted therapy, hormonal therapy, chemotherapy and immunotherapy. The targeted therapy segment exceeded USD 19 Billion in 2022 anticipating a substantial growth in coming years. This substantial market dominance is attributed to its adaptability for combination with other treatments, the emergence of personalized approaches to enhance clinical outcomes, and continuous advancements.
 

• Ongoing clinical studies have widened the scope of targeted therapies to include multiple molecules in targetable pathways including the epidermal growth factor receptor (EGFR), poly (adenosine diphosphate-ribose) polymerase (PARP), and cyclin-dependent kinase 4/6 (CDK4/6).
   
• Further, developments in treatment for metastatic hormone receptor-positive breast cancer have promoted the use of targeted therapies. Majority of the treatment guidelines, including the National Comprehensive Cancer Network suggests the use of targeted therapeutic options with artificial intelligence or selective ER modulators rather than chemotherapy.
   

The North America breast cancer therapeutics market is expected to grow at 6.8% during the analysis period.
 

• This dominant market share is attributable to several factors such as the high incidence of breast cancer, steadily rising disease burden, and presence of major market players among others. According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases. The Globocan 2020 reported that the incidence of breast cancer was 253,465 cases in the U.S. Thus, the high incidence and prevalence of breast cancer inflicts significant mortality along with disease burden. The rising disease burden in the country is anticipated to promote the demand for breast cancer therapeutics.
   
• Further, the presence of major market players and favorable reimbursement scenario for breast cancer treatment would drive the acceptance rate of breast cancer therapeutics.
   

Breast Cancer Therapeutics Market Share

The players operating in this market have established themselves through continuous research & development and ensuring high-quality products. Pfizer, Bristol Myer Squibb, Amgen, F-Hoffmann La Roche, and Merck account for significant market share in the overall breast cancer therapeutics. The leading companies are making substantial investments in product improvements while giving priority to competitive pricing as a strategic approach, anticipating remarkable market expansion.
 

Market players operating in the breast cancer therapeutics is as mentioned below:

• AstraZeneca plc.
• Eli Lilly & Co, Inc.
• Pfizer, Inc.
• Novartis AG
• Amgen
• F. Hoffmann La Roche AG
• Merck & Co, Inc.
• Gilead Sciences, Inc.
• Eisai Co., Ltd.
• Macrogenics, Inc.

Breast Cancer Therapeutics Industry News:

• In February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy to treat adult patients with inoperable locally advanced or metastatic breast cancer. This approval anticipates enhancing the available treatment choices and likely leading to improved outcomes for patients suffering from breast cancer.
   
• In November 2021, AstraZeneca and Merck Sharpe & Dohme’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) was granted Priority Review in the U.S. intended for the adjuvant treatment of patients suffering with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer. Lynparza is currently being jointly developed & commercialized by AstraZeneca and MSD. This strategic collaboration helped both the company to gain competitive advantage and strengthen their market position.
   

The breast cancer therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Therapy 2018 – 2032 (USD Million)

• Targeted therapy
• Hormonal therapy
• Chemotherapy
• Immunotherapy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa